MDNAF - Medicenna to Host Virtual Roadshow Webinar

Canada NewsWire

TORONTO and HOUSTON, TX, Jan. 25, 2019

January 29^th, 2019 at 2:00 p.m. ET

TORONTO and HOUSTON, TX, Jan. 25, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced that it will host a virtual roadshow webinar on January 29^th, 2019 at 2:00 p.m. Eastern Time.

Fahar Merchant, the Company's President and Chief Executive Officer, and Elizabeth Williams, Chief Financial Officer, will be presenting an overview of Medicenna's business model and growth initiatives. The webinar will include a slide presentation followed by a question and answer session, which can be accessed via the webcast link or dial-in numbers below.

To access the webinar, please use the following information:

Date: Tuesday, January 29, 2019
Time: 2:00 p.m. Eastern Time (11:00 a.m. Pacific Time)
Dial-In: 1-877-407-9039
International Dial-In: 1-201-689-8470
Conference Code: 13686955
Webcast: http://public.viavid.com/index.php?id=133045

A telephone replay will be available approximately two hours after the call and will run through February 12, 2019 by dialing 1-844-512-2921 from the U.S., or 1-412-317-6671 from international locations, and entering replay pin number: 13686955.

The webcast replay can also be viewed through the link above for a period of 90 days following the event.

About Medicenna

Medicenna is a clinical stage immunotherapy company focused on oncology and the development and commercialization of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Cytokinesâ„¢ (ECs) for the treatment of a broad range of cancers. Medicenna's wholly owned subsidiary, Houston-based Medicenna Biopharma Inc., is specifically targeting the Interleukin-4 Receptor (IL4R), which is over-expressed by at least 20 different types of cancer affecting more than one million new cancer patients every year. Supported by a significant non-dilutive grant from CPRIT (Cancer Prevention and Research Institute of Texas), Medicenna's lead IL4-EC, MDNA55, is enrolling patients in a Phase 2b clinical trial for rGBM, the most common and uniformly fatal form of brain cancer, at top-ranked brain cancer centres in the US. MDNA55 has completed three clinical trials in 72 patients, including 66 adults with rGBM, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA respectively. For more information, please visit www.medicenna.com.

SOURCE Medicenna Therapeutics Corp.

View original content: http://www.newswire.ca/en/releases/archive/January2019/25/c0852.html